Steba Biotech is a biotechnology company focused on targeting cancer with a minimally invasive approach using a specialmolecule and focused light. Steba is utilizinga novel molecule, focal vascular occluding agent (FVOA), licensed from the Weizmann Institute, in its TOOKAD Soluble drug. TOOKAD Soluble acts as a sensitizer and works with a focused light beam to destroy early-stage prostate cancer cells. The light is delivered to the site through a thin optical fiber. Once the sensitizer is activated by the light, it triggers a process that ultimately cuts off the blood supply to the tumors. Steba Biotech is a private company with its headquarters in Luxembourg and branch companies in France, Israel, USA, Brazil and Switzerland.